ArticleBMC cancer2021
Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis.JNCI cancer spectrum · 2023Pooled it
- Article
- [Clinicopathological features and prognostic factors associated with long-term survival (≥5 years) in patients with clear cell renal cell carcinoma and venous tumor thrombus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Article
- Venous Tumor Thrombus Level in Renal Cell Carcinoma: Impact on Surgical and Oncologic Outcomes.Cancers · 2026Review
- Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Impact of perirenal collateral on the surgical management and prognosis of nonmetastatic renal cell carcinoma and inferior vena cava tumor thrombus.Abdominal radiology (New York) · 2026Article
- Prognostic gene screening and experimental validation in renal clear cell carcinoma based on spatial transcriptomics and single-cell sequencing.Frontiers in immunology · 2026Article
- Surgical management of renal cell carcinoma with extension into the inferior vena cava and right atrium: A case report.International journal of surgery case reports · 2025Article
- Reviewing the Current State of Renal Cell Carcinoma with a Tumor Thrombus: Epidemiology, Pathophysiology, Metastasis, and Systemic Therapy.Current urology reports · 2025Review
- Is Preoperative Anticoagulation in Nephrectomy with Caval Thrombectomy Necessary? A Multicenter Retrospective Cohort Study.European urology open science · 2025Article
- Radiomic Profiling of Tumor Thrombus for Predicting Recurrence in Renal Cell Carcinoma.European urology open science · 2025Article
- Upregulation ofInternational journal of molecular sciences · 2025Article
- A comparison of open, laparoscopic, and robotic radical nephrectomy with tumor thrombectomy from the intercontinental collaboration on renal cell carcinoma.Journal of robotic surgery · 2025Article
- Comparative analysis of oncologic outcomes in surgically treated patients with renal cell carcinoma and renal vein thrombosis by pathologic subtypes.Scientific reports · 2025Article
- Late Survival and Long-Term Follow-Up After Radical Resection of Advanced Renal Cell Carcinoma With Associated Venous Tumor Thrombus.Journal of surgical oncology · 2025Article
- Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).World journal of urology · 2025Article
- Radical nephrectomy with inferior vena cava tumor thrombectomy in Mayo III-IV renal cell carcinoma: a retrospective single-center study.Frontiers in surgery · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe surgical management and outcomes of renal cell carcinoma (RCC) with venous tumor thrombus (VTT) have been reported in limited sample size, and there remain discrepancies over the factors that influence oncologic outcomes after radical nephrectomy with thrombectomy (RNTE). The aim of the study was to analyze the outcomes of the patients with RCC with VTT in our institution and identify the independent prognostic factors.
methodsPatients with RCC with VTT were enrolled for the study from February 2015 to December 2018. All patients underwent RNTE. Clinical data were compared using Mann-Whitney U test and the chi-square test for continuous and categorical variables respectively. Survival analysis was estimated using the Kaplan-Meier method. Univariable and multivariable survival analyses were performed using Cox regression model.
results121 patients (91 men & 30 women) were identified with a median age of 60 years. VTT level was 0 in 25 patients, I in 20, II in 50, III in 12 and IV in 14. The median follow-up time was 24 months. During the follow-up period, 51 (42%) patients died and 69 (57%) patients experienced recurrence or metastasis. The 3-year and 5-year over-all survival (OS) were 58 and 39%. Among the several factors examined, positive lymph node (P = 0.016), metastasis at surgery (P = 0.034), tumor necrosis (P = 0.023) and sarcomatoid differentiation (P < 0.001) were demonstrated as independent significant risk factors on multivariable analysis.
conclusionThe OS was poor for patients with RCC with VTT. Rather than VTT level, positive lymph node, metastasis at surgery, tumor necrosis and sarcomatoid differentiation were independent prognostic predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.